This article introduces recently IPO-listed companies in Japan while highlighting key challenges, business opportunities, industry trends, and unique business models in the Japanese market.
VERITAS IN SILICO INC, headquartered in Shinagawa, Tokyo, is a biotechnology company specializing in drug discovery technology rather than pharmaceutical manufacturing. The company focuses on developing a platform for mRNA-targeted small-molecule and nucleic acid drug discovery, utilizing in silico (computer-based) technology to analyze RNA structures and create new drug development methods.
By targeting structural motifs on mRNA, VERITAS IN SILICO’s approach enables the discovery of treatments for diseases that are difficult to address with conventional protein-targeted drug discovery. This innovation is expected to bring a paradigm shift to the pharmaceutical industry.
Despite being recognized for its unique business model and technological potential, the company faced financial challenges in fiscal year 2024, as it was unable to secure expected contracts. As a result, revenue declined, and the company reported a net loss. However, VERITAS IN SILICO aims for significant revenue and profit growth in the next fiscal year, driven by new business developments and contract acquisitions.
The company achieved a key milestone by successfully listing on the Tokyo Stock Exchange Growth Market on February 8, 2024, supporting its long-term growth strategy.
| Company Name | Veritas In Silico Inc. |
| Headquarters | 1-11-1 Nishi-Gotanda, Shinagawa-ku, Tokyo |
| Website | https://www.veritasinsilico.com/en/ |
| Year of Establishment | 17th November 2016 |
| Listing Date | 8th February 2024 |
| Industry | Biotechnology |
| Business Overview | Platform business for small-molecule drug discovery and nucleic acid drug discovery targeting mRNA |
| Representative (CEO) | Shingo Nakamura |
| Number of Employees | 15 (as of 11/30/2023) |
| Stock Exchange | TSE Growth |
| Auditor | Toyo |
| Lead Underwriter | Mizuho Securities Co. |
| Market capitalization (at opening price) | 12,609 million yen |
| PER (at opening price) | – |
| Major shareholders (Top 3) | •Shingo Nakamura(23.33%) •Mitsubishi Gas Chemicals Corporation (11.96%) •New Life Science No.1 Investment Limited Partnership (9.10%) |
This document has been prepared based on information available at the time of the research. While we strive for accuracy, we do not guarantee the completeness or correctness of the information provided. This document is for informational purposes only and does not constitute investment advice or a recommendation. Readers are encouraged to conduct their own verification and due diligence before making any decisions.
Source: Tokyo IPO, Official Website, Yahoo! Finance
